Source:http://linkedlifedata.com/resource/pubmed/id/12843744
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2003-7-4
|
pubmed:abstractText |
An increasing number of HIV-1-infected patients living in developing countries now have access to antiretroviral drugs. Information regarding the drug-resistant mutations of non-B subtype HIV-1 remains limited, however. The authors cross-sectionally compared patterns of the drug-resistant point mutations in patients infected with either subtype B or CRF01_AE (subtype E) among patients who acquired HIV by sexual transmission in Japan. Protease sequence data were available from 216 patients with a detectable level of RNA copies in plasma. Based on phylogenetic analysis of the protease and the C2V3 regions, 162 subtype B and 45 CRF01_AE cases were identified; 82 subtype B and 24 CRF01_AE patients had a treatment failure with nucleoside reverse transcriptase inhibitors; and 69 subtype B and 19 CRF01_AE patients had a treatment failure with a protease inhibitor. Antiretroviral drug history was similar in subtype B-infected and CRF01_AE-infected patients. The mutations T69N and V75M in reverse transcriptase and L10F, K20I, L33I, and N88S in protease were seen more frequently in patients infected with CRF01_AE than in patients with subtype B. The mutations, D30N, A71V, and N88D were found exclusively in patients with subtype B. Most of the characteristic mutation patterns were associated with a history of receiving nelfinavir. The pattern of drug resistance mutations differs between the subtypes. Data derived from subtype B drug-resistant genotypes may not always be applicable to non-B subtypes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1525-4135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
336-42
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:12843744-Adult,
pubmed-meshheading:12843744-Aged,
pubmed-meshheading:12843744-Anti-HIV Agents,
pubmed-meshheading:12843744-DNA Mutational Analysis,
pubmed-meshheading:12843744-Drug Resistance, Multiple, Viral,
pubmed-meshheading:12843744-Female,
pubmed-meshheading:12843744-Genetic Variation,
pubmed-meshheading:12843744-HIV Infections,
pubmed-meshheading:12843744-HIV Protease,
pubmed-meshheading:12843744-HIV Reverse Transcriptase,
pubmed-meshheading:12843744-HIV-1,
pubmed-meshheading:12843744-Humans,
pubmed-meshheading:12843744-Male,
pubmed-meshheading:12843744-Middle Aged,
pubmed-meshheading:12843744-Point Mutation,
pubmed-meshheading:12843744-Treatment Failure
|
pubmed:year |
2003
|
pubmed:articleTitle |
Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.
|
pubmed:affiliation |
AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|